BOUNDLESS BIO INC (BOLD) Stock News
NASDAQ:BOLD - Nasdaq - US10170A1007 - Common Stock - Currency: USD
BOLD Latest News, Press Relases and Analysis
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)...
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of...
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Boundless Bio (NASDAQ:BOLD) just reported results for the second quarter of 202...
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024
BOLD stock results show that Boundless Bio beat analyst estimates for earnings per share the second quarter of 2024.
BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024
Boundless Bio just reported results for the first quarter of 2024.
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer...
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers -
Audentes Therapeutics (BOLD) Gets a Hold Rating from Chardan Capital
Chardan Capital analyst Gbola Amusa maintained a Hold rating on Audentes Therapeutics (BOLD – Research Report) on January 18. The company’s shares closed last Monday at $59.97, close to its 52-week high of $60.00. According to TipRanks.com, Amusa is a top 100 analyst with an average return of 27.5% and a 53.6% success rate. Amusa
Boundless Bio Announces Pipeline and Leadership Updates
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate...
Boundless Bio Announces Pipeline and Leadership Updates
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)...
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 ...
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)...
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
Boundless Bio Announces Departure of Chief Financial Officer
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)...
Boundless Bio Announces Departure of Chief Financial Officer
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA)...
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now...
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
Bayer-Backed Boundless Bio Falls 9% After $100 Million IPO
Shares of Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, fell 9% after raising $100 million in a US initial public offering.
Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO
Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, raised $100 million in a US initial public offering after pricing shares at the midpoint of a marketed range.
Boundless Bio Announces Pricing of Initial Public Offering
IPO Previews For The Week
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.
Mentions: MMA
Thomas M. Soloway on Satsuma Pharma's board (NASDAQ:STSA)
Satsuma Pharmaceuticals (STSA -0.3%) appointed industry veteran Thomas M. Soloway, currently serving as EVP and COO of Audentes Therapeutics (BOLD), to its board of directors, effective July 2, 2020.Prior to joining Audentes, Mr.